Ticker
ACAD

Price
16.84
Stock movement down
-0.30 (-1.75%)
Company name
ACADIA Pharmaceuticals Inc
Exchange
(NASDAQ
,
Currency
USD
)
Sector
Healthcare >
Biotechnology
Market cap
2.72B
Ent value
2.69B
Price/Sales
5.51
Price/Book
6.11
Div yield
-
Div growth
-
Growth years
-
FCF payout
-
Trailing P/E
-
Forward P/E
-
PEG
-
EPS growth
-
1 year return
-1.98%
3 year return
-15.41%
5 year return
-12.00%
10 year return
25.85%
Last updated: 2022-08-25

DIVIDENDS

ACAD does not pay dividends

VALUATION

Valuation Ratios

Loading...
Valuation Ratios data
Trailing P/E-
Price to OCF-
Price to FCF-
Price to EBITDA-
EV to EBITDA-

Valuation (Sales/Book Value)

Loading...
Valuation (Sales/Book Value) data
Price to Sales5.51
Price to Book6.11
EV to Sales5.46

FINANCIALS

Per share

Loading...
Per share data
Current share count161.43M
EPS (TTM)-1.33
FCF per share (TTM)-0.88

Income statement

Loading...
Income statement data
Revenue (TTM)493.06M
Gross profit (TTM)475.66M
Operating income (TTM)-216.68M
Net income (TTM)-214.48M
EPS (TTM)-1.33
EPS (1y forward)-0.74

Margins

Loading...
Margins data
Gross margin (TTM)96.47%
Operating margin (TTM)-43.95%
Profit margin (TTM)-43.50%

Balance Sheet

Loading...
Please create a free account or log in to access this chart
Balance Sheet data
Cash204.92M
Net receivables63.48M
Total current assets542.22M
Goodwill0.00
Intangible assets0.00
Property, plant and equipment0.00
Total assets624.25M
Accounts payable10.77M
Short/Current long term debt64.42M
Total current liabilities119.60M
Total liabilities179.45M
Shareholder's equity444.80M
Net tangible assets444.80M

Cash flow

Loading...
Please create a free account or log in to access this chart
Cash flow data
Operating cash flow (TTM)-141.84M
Capital expenditures (TTM)47.00K
Free cash flow (TTM)-141.89M
Dividends paid (TTM)0.00

Financial returns

Loading...
Please create a free account or log in to access this chart
Financial returns data
Return on Equity-48.22%
Return on Assets-34.36%
Return on Invested Capital-48.22%
Cash Return on Invested Capital-31.90%

STOCK INFORMATION

Stock chart

Loading...
Stock price data
Open17.28
Daily high17.34
Daily low16.62
Daily Volume871K
All-time high57.00
1y analyst estimate22.06
Beta0.72
EPS (TTM)-1.33
Dividend per share-
Ex-div date-
Next earnings date7 Nov 2022

Downside potential

Loading...
Downside potential data
ACADS&P500
Current price drop from All-time high-70.46%-12.18%
Highest price drop-96.29%-56.47%
Date of highest drop12 Nov 20109 Mar 2009
Avg drop from high-47.36%-11.38%
Avg time to new high50 days12 days
Max time to new high1820 days1805 days
COMPANY DETAILS
ACAD (ACADIA Pharmaceuticals Inc) company logo
Marketcap
2.72B
Marketcap category
Mid-cap
Description
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's pipeline include, pimavanserin, under phase 3 development for the treatment of Alzheimer's disease psychosis, and negative symptoms of schizophrenia; Trofinetide, a novel synthetic analog, under phase 3 development for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic, under phase 2 development for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor, under phase 1 development for treating schizophrenia and cognition in Alzheimer's. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.
Employees
500
Investor relations
-
SEC filings
CEO
Stephen R. Davis
Country
USA
City
San Diego
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
The FDA accepts and grants priority review to Acadia's (ACAD) NDA for trofinetide to treat Rett syndrome. A decision from the regulatory body is due on Mar 12, 2023.
September 13, 2022
SAN DIEGO, September 12, 2022--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing its New Drug Application (NDA) of tro...
September 12, 2022
Acadia (ACAD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
September 7, 2022
SAN DIEGO, September 01, 2022--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate at the following upcoming investor conferences:
September 1, 2022
The mean of analysts' price targets for Acadia (ACAD) points to a 26.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts ...
August 30, 2022
Acadia (ACAD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
August 26, 2022
Acadia Pharmaceuticals Inc (NASDAQ: ACAD) stopped working on two candidates, including a one-time competitor to Vertex Pharmaceuticals Incorporated's (NASDAQ: VRTX) non-opioid painkiller. The company ...
August 9, 2022
Acadia (ACAD) reports a narrower-than-expected loss for the second quarter of 2022 while revenues surpass estimates. Tightens guidance for Nuplazid.
August 9, 2022
Acadia (ACAD) delivered earnings and revenue surprises of 16% and 2.82%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
August 8, 2022
SAN DIEGO, August 08, 2022--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD), today announced its financial results for the second quarter ended June 30, 2022.
August 8, 2022
Next page